Eyenovia Inc (EYEN) - Net Assets
Based on the latest financial reports, Eyenovia Inc (EYEN) has net assets worth $-9.71 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.98 Million) and total liabilities ($15.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Eyenovia Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.71 Million |
| % of Total Assets | -162.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | -185.57% |
| 10-Year Change | N/A |
| Growth Volatility | 117.63 |
Eyenovia Inc - Net Assets Trend (2015–2024)
This chart illustrates how Eyenovia Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Eyenovia Inc for the complete picture of this company's asset base.
Annual Net Assets for Eyenovia Inc (2015–2024)
The table below shows the annual net assets of Eyenovia Inc from 2015 to 2024. For live valuation and market cap data, see how much is Eyenovia Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-13.10 Million | -245.53% |
| 2023-12-31 | $9.00 Million | -47.78% |
| 2022-12-31 | $17.23 Million | -15.79% |
| 2021-12-31 | $20.47 Million | +33.73% |
| 2020-12-31 | $15.30 Million | +30.35% |
| 2019-12-31 | $11.74 Million | -30.43% |
| 2018-12-31 | $16.88 Million | +231.49% |
| 2017-12-31 | $5.09 Million | +69.18% |
| 2016-12-31 | $3.01 Million | +25.46% |
| 2015-12-31 | $2.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eyenovia Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18471223600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $151.00 | % |
| Other Components | $182.21 Million | % |
| Total Equity | $-13.10 Million | 100.00% |
Eyenovia Inc Competitors by Market Cap
The table below lists competitors of Eyenovia Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hwang-Kum Stee
KO:032560
|
$73.34 Million |
|
Solutions 30 SE
PA:S30
|
$73.34 Million |
|
Great Computer
TWO:8047
|
$73.38 Million |
|
Central Plains Bancshares, Inc. Common Stock
NASDAQ:CPBI
|
$73.39 Million |
|
TV Today Network Limited
NSE:TVTODAY
|
$73.29 Million |
|
Sab Zenzele Kabili Holdings
JSE:SZK
|
$73.27 Million |
|
Min Aik Precision Industrial Co Ltd
TW:4545
|
$73.26 Million |
|
Mercer International Inc
F:AEZ
|
$73.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eyenovia Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,999,094 to -13,095,952, a change of -22,095,046 (-245.5%).
- Net loss of 49,818,433 reduced equity.
- New share issuances of 25,619,417 increased equity.
- Other factors increased equity by 2,103,970.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.82 Million | -380.41% |
| Share Issuances | $25.62 Million | +195.63% |
| Other Changes | $2.10 Million | +16.07% |
| Total Change | $- | -245.53% |
Book Value vs Market Value Analysis
This analysis compares Eyenovia Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $16.09 | $14.36 | x |
| 2016-12-31 | $20.19 | $14.36 | x |
| 2017-12-31 | $34.15 | $14.36 | x |
| 2018-12-31 | $118.71 | $14.36 | x |
| 2019-12-31 | $54.55 | $14.36 | x |
| 2020-12-31 | $48.46 | $14.36 | x |
| 2021-12-31 | $51.83 | $14.36 | x |
| 2022-12-31 | $34.15 | $14.36 | x |
| 2023-12-31 | $14.62 | $14.36 | x |
| 2024-12-31 | $-15.72 | $14.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eyenovia Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -86888.57%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-133.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -177.91% | 0.00% | 0.00x | 1.18x | $-4.51 Million |
| 2016 | -117.43% | 0.00% | 0.00x | 1.14x | $-3.83 Million |
| 2017 | -100.77% | 0.00% | 0.00x | 1.11x | $-5.64 Million |
| 2018 | -102.24% | 0.00% | 0.00x | 1.19x | $-18.94 Million |
| 2019 | -178.78% | 0.00% | 0.00x | 1.25x | $-22.16 Million |
| 2020 | -128.67% | -984.57% | 0.06x | 2.22x | $-21.22 Million |
| 2021 | -63.48% | -92.80% | 0.44x | 1.55x | $-15.04 Million |
| 2022 | -160.90% | -277.31% | 0.32x | 1.80x | $-29.45 Million |
| 2023 | -302.93% | -719859.94% | 0.00x | 3.20x | $-28.16 Million |
| 2024 | 0.00% | -86888.57% | 0.02x | 0.00x | $-48.51 Million |
Industry Comparison
This section compares Eyenovia Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eyenovia Inc (EYEN) | $-9.71 Million | -177.91% | N/A | $73.30 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Eyenovia Inc
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vi… Read more